Indication
In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤10 x 103/µl), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene

Medicine details

Medicine name:
arsenic trioxide (Trisenox)
SMC ID:
SMC2025
Pharmaceutical company
Teva UK Limited
BNF chapter
Submission type
Full submission
Status
Advice due date:
14 January 2019
SMC meeting date:
04 December 2018
Patient group submission deadline:
01 October 2018